Summary
A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non–small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non–small cell lung cancer and triple-negative breast cancer.
This content is only available via PDF.
©2024 American Association for Cancer Research
2024
American Association for Cancer Research
You do not currently have access to this content.